In the recent past, the management of Foresite Capital recruited the services of Molly He, PhD. Dr. Molly will serve as a venture partner for the healthcare growth equity company. She has over 15 years of experience in genomic research and development and pharmaceutical. Formerly, the executive was a senior director for Illumina. Jim Tananbaum, the CEO of Foresite Capital, posited that Dr. Molly has vast experience in in the next-generation sequencing. He added that they were thrilled to have her as part of the company’s management team. Jim in an Interview asserted that Dr. Molly’s extensive experience in drug development and genomics coupled with her tranformative leadership would be of great value to the corporation. Notably, Foresite Capital is planning to enhance its portfolio.
At Illumina, Dr. He was charged with the duty of engaging in improvements and innovation of global protein reagent. Previously, she worked for Pacific Biosciences. Here, she was responsible for the development of protein reagent for the entity’s real-time sequencing chemistry. Earlier, she spent a decade in the pharmaceutical industry where she zeroed in on structural based design of small molecule drugs focusing on cancer and immune diseases and antibody.
Dr. Molly is a proud alumnus of Nankai University where she graduated with her undergraduate degree in biochemistry. Moreover, she holds a PhD in protein biophysics from the renowned University of California, Los Angeles. Notably, the executive has published more than 20 papers. In addition, Dr. He has over 20 patent applications and issued patents in personalized medicine and next-generation sequencing.
In her speech, Dr. He posited that Foresite Capital is reputable for investing in some of the leading and innovative healthcare corporations. She was honored to join the dynamic and seasoned team to help them in growing the company’s next-generation sequencing portfolio.
About Jim Tananbaum
Jim is a graduate of Yale University, Harvard University and Massachusetts Institute of Technology (MIT). Before incorporating Foresite Capital, Jim had co-founded two renowned pharmaceutical companies. These firms are GelTex Pharmaceuticals and Theravance. The combined market capitalization of the two companies is approximately $3.2 billion.
Tananbaum has over 25 years of experience as a healthcare entrepreneur. Over the years, Jim has been focusing on financial, operational and strategic opportunities to develop successful healthcare businesses. Read more about Tananbaum on ideamensch.com.